^
Association details:
Biomarker:PD-1 expression
Cancer:Cutaneous Melanoma
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma

Published date:
07/21/2022
Excerpt:
The purpose of this study was to construct a ferroptosis-related lncRNA signature to predict prognosis and immunotherapy efficacy in CM….Low-risk patients whose disease expressed PD1 or CTLA4 were likely to respond better to ICIs.
DOI:
10.3389/fsurg.2022.860806